SPHINGOSINE 1-PHOSPHATE RECEPTOR 5

Approval Year

Substance Class	Protein Created by `admin` on `Tue Apr 01 17:07:18 GMT 2025` Edited by `admin` on `Tue Apr 01 17:07:18 GMT 2025`
Protein Sub Type
Sequence Type	COMPLETE
Record UNII	3UW2OFC4M0
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

EDG8

Preferred Name

English

SPHINGOSINE 1-PHOSPHATE RECEPTOR 5

Common Name

English

SPHINGOSINE 1-PHOSPHATE RECEPTOR EDG-8

Common Name

English

ENDOTHELIAL DIFFERENTIATION G-PROTEIN-COUPLED RECEPTOR 8

Common Name

English

S1P RECEPTOR EDG-8

Common Name

English

S1P RECEPTOR 5

Common Name

English

Code System Code Type Description

PHAROS

Q9H228

Created by admin on Tue Apr 01 17:07:18 GMT 2025 , Edited by admin on Tue Apr 01 17:07:18 GMT 2025

PRIMARY

FDA UNII

3UW2OFC4M0

Created by admin on Tue Apr 01 17:07:18 GMT 2025 , Edited by admin on Tue Apr 01 17:07:18 GMT 2025

PRIMARY

UNIPROT

Q9H228

Created by admin on Tue Apr 01 17:07:18 GMT 2025 , Edited by admin on Tue Apr 01 17:07:18 GMT 2025

PRIMARY

Glycosylation Type

HUMAN

Glycosylation Link Type	Site
N	1_20

Related Record Type Details


					6WH8495MMH

ETRASIMOD

PARTIAL AGONIST->TARGET

Comments:

Relative efficacY of 63% of S1P1 activity 73%

Qualification:

EC50

Amount:


					KYS7WW026H

RP-100798

AGONIST -> TARGET

Interaction Type:

SELECTIVE


					Q2Q3WJK6VL

PR-101442

AGONIST -> TARGET

Interaction Type:

SELECTIVE


					Y333RS1786

CENERIMOD

AGONIST -> TARGET

Comments:

Chinese Hamster Ovary (CHO) cells, overexpressing human S1P5 receptor (35S)-GTP-S incorporation assays.

Qualification:

EC50

Amount:


					92YDM6122J

FINGOLIMOD PHOSPHATE ESTER, (S)-

AGONIST -> TARGET

Amount:


					APE8X7S2BU

1-[[(3S)-3,4-Dihydro-3-methyl-6-(4,4,4-trifluorobutoxy)-2-naphthalenyl]methyl]-3-azetidinecarboxylic acid

AGONIST -> TARGET

Amount:


					BZ2O8A84A4

CERALIFIMOD

AGONIST -> TARGET

Amount:


					Z80293URPV

Ozanimod

AGONIST -> TARGET

Interaction Type:

SELECTIVE

Amount:


					RR6P8L282I

Siponimod

AGONIST -> TARGET

Comments:

Blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in peripheral blood. Initial receptor activation is paradoxically followed by S1P1 functional antagonism, whereby receptors are internalized and degraded, thus reducing or eliminating them from the lymphocyte cell surface.40,60,70,74,75 This down-regulation renders lymphocytes unresponsive to the normal S1P gradient and thus deprives them of the obligatory signal that would ordinarily allow them to egress from lymphoid tissues and recirculate to the periphery.

Amount: